Methyllycaconitine citrate (Standard)
Methyllycaconitine citrate (Standard) is the analytical standard of Methyllycaconitine citrate (HY-N2332A). This product is intended for research and analytical applications. Methyllycaconitine (MLA) citrate is a blood-brain barrier-permeable antagonist of α7 nicotinic acetylcholine receptor (α7nAChR) with an IC50 of 2 nM. Methyllycaconitine citrate inhibits Aβ25-35-induced autophagy by restoring the mTOR pathway, and prevents reactive oxygen species (ROS) production, microglial activation, reduced dopamine uptake, loss of dopaminergic terminals and catecholamine secretion. Methyllycaconitine citrate induces hippocampal glutamate efflux, enhances long-term potentiation, and improves memory acquisition. Methyllycaconitine citrate can be used in research related to Alzheimer's disease, cerebral palsy, ParKinson's disease and schizophrenia.
For research use only. We do not sell to patients.
- CAS No.: 351344-10-0
- Formula: C43H58N2O17
- Molecular Weight:874.92
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 351344-10-0
-
Molecular Weight 874.92
-
Formula C43H58N2O17
-
SMILES
CO[C@@H]1C(C(N(CC)C2)C3(O)[C@H]4OC)([C@@](C[C@@]5([H])[C@@H]6OC)([H])[C@@]6([H])[C@@]3(C[C@@H]5OC)O)[C@@]4([H])[C@@]2(COC(C7=C(N(C8=O)C(C[C@@H]8C)=O)C=CC=C7)=O)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O
-
Synonyms
MLA citrate (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Zheng X, et al. Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. PloS one. 2014;9(10):e111536. [Content Brief]
[2]. Escubedo E, et al. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors. The Journal of pharmacology and experimental therapeutics. 2005 Nov;315(2):658-67. [Content Brief]
[3]. Qasem AMA, et al. Synthesis and Antagonist Activity of Methyllycaconitine Analogues on Human α7 Nicotinic Acetylcholine Receptors. ACS bio & med chem Au. 2023 Apr 19;3(2):147-157. [Content Brief]
[4]. van Goethem NP, et al. Antagonizing α7 nicotinic receptors with methyllycaconitine (MLA) potentiates receptor activity and memory acquisition. Cellular signalling. 2019 Oct;62:109338. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Methyllycaconitine citrate (Standard) Related Classifications
HY-N2332AR Related Classifications
Powered by Bioz
Keywords
- Methyllycaconitine citrate (Standard)
- 351344-10-0
- MLA citrate (Standard)
- Reference Standards
- nAChR
- Autophagy
- Reactive Oxygen Species (ROS)
- mTOR
- Swiss CD-1 mice
- mTOR pathway
- α7 nicotinic acetylcholine receptor
- human α7 nAChR
- Wistar rats
- SH-SY5Y cells
- Aβ25-35
- Xenopus laevis oocytes
- Sprague Dawley rats
- bovine α3β4 nAChR
- Inhibitor
- inhibitor
- inhibit